Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 2Phase 1/2 2Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Sarcoma 1Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Melanoma 2Urinary Bladder Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Esophageal Neoplasms 1Chondrosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Adenocarcinoma 1

Interventions

pembrolizumab 74Nivolumab 53Ipilimumab 42Cyclophosphamide 32Interleukin-2 24aldesleukin 23Temozolomide 17fludarabine 16Biopsy 11trametinib 10fludarabine phosphate 10dabrafenib 10spartalizumab 8Paclitaxel 8Dacarbazine 8sargramostim 7cemiplimab 7binimetinib 7Cisplatin 7Bevacizumab 7poly ICLC 6lenvatinib 6epacadostat 6Radiotherapy 6Granulocyte-Macrophage Colony-Stimulating Factor 6montanide ISA 51 5encorafenib 5atezolizumab 5Vemurafenib 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Melanoma × resiquimod × Clear all
NCT02126579 2024-02-28

MEL60

University of Virginia

Phase 1/2 Completed
50 enrolled 13 charts
Dermatologic

Melanoma, Neoplasms

NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡